Takeda Pharmaceutical Statistics

Total Valuation

Takeda Pharmaceutical has a market cap or net worth of $47.09 billion. The enterprise value is $79.65 billion.

Market Cap	47.09B
Enterprise Value	79.65B

Important Dates

The next estimated earnings date is Wednesday, July 30, 2025, before market open.

Earnings Date	Jul 30, 2025
Ex-Dividend Date	Sep 30, 2024

Share Statistics

Takeda Pharmaceutical has 1.57 billion shares outstanding. The number of shares has increased by 1.58% in one year.

Current Share Class	n/a
Shares Outstanding	1.57B
Shares Change (YoY)	+1.58%
Shares Change (QoQ)	-0.21%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.56B

Valuation Ratios

The trailing PE ratio is 65.34.

PE Ratio	65.34
Forward PE	n/a
PS Ratio	1.54
Forward PS	0.04
PB Ratio	1.02
P/TBV Ratio	n/a
P/FCF Ratio	7.96
P/OCF Ratio	6.67
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.67, with an EV/FCF ratio of 13.46.

EV / Earnings	110.52
EV / Sales	2.60
EV / EBITDA	9.67
EV / EBIT	21.19
EV / FCF	13.46

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.73.

Current Ratio	1.01
Quick Ratio	0.44
Debt / Equity	0.73
Debt / EBITDA	3.96
Debt / FCF	5.74
Interest Coverage	4.31

Financial Efficiency

Return on equity (ROE) is 1.52% and return on invested capital (ROIC) is 2.84%.

Return on Equity (ROE)	1.52%
Return on Assets (ROA)	2.40%
Return on Invested Capital (ROIC)	2.84%
Return on Capital Employed (ROCE)	4.79%
Revenue Per Employee	$620,829
Profits Per Employee	$14,625
Employee Count	49,281
Asset Turnover	0.31
Inventory Turnover	1.29

Taxes

In the past 12 months, Takeda Pharmaceutical has paid $447.02 million in taxes.

Income Tax	447.02M
Effective Tax Rate	38.23%

Stock Price Statistics

The stock price has increased by +16.03% in the last 52 weeks. The beta is 0.26, so Takeda Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.26
52-Week Price Change	+16.03%
50-Day Moving Average	14.82
200-Day Moving Average	14.21
Relative Strength Index (RSI)	54.48
Average Volume (20 Days)	2,017,791

Short Selling Information

Short Interest	6.24M
Short Previous Month	4.68M
Short % of Shares Out	0.40%
Short % of Float	0.40%
Short Ratio (days to cover)	2.86

Income Statement

In the last 12 months, Takeda Pharmaceutical had revenue of $30.60 billion and earned $720.73 million in profits. Earnings per share was $0.45.

Revenue	30.60B
Gross Profit	20.10B
Operating Income	3.76B
Pretax Income	366.81M
Net Income	720.73M
EBITDA	8.24B
EBIT	3.76B
Earnings Per Share (EPS)	$0.45

Full Income Statement

Balance Sheet

The company has $2.57 billion in cash and $33.98 billion in debt, giving a net cash position of -$31.41 billion or -$19.96 per share.

Cash & Cash Equivalents	2.57B
Total Debt	33.98B
Net Cash	-31.41B
Net Cash Per Share	-$19.96
Equity (Book Value)	46.32B
Book Value Per Share	29.43
Working Capital	97.97M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $7.06 billion and capital expenditures -$1.34 billion, giving a free cash flow of $5.92 billion.

Operating Cash Flow	7.06B
Capital Expenditures	-1.34B
Free Cash Flow	5.92B
FCF Per Share	$3.76

Full Cash Flow Statement

Margins

Gross margin is 65.70%, with operating and profit margins of 12.29% and 2.36%.

Gross Margin	65.70%
Operating Margin	12.29%
Pretax Margin	3.82%
Profit Margin	2.36%
EBITDA Margin	26.92%
EBIT Margin	12.29%
FCF Margin	19.35%

Dividends & Yields

This stock pays an annual dividend of $0.27, which amounts to a dividend yield of 1.77%.

Dividend Per Share	$0.27
Dividend Yield	1.77%
Dividend Growth (YoY)	-1.77%
Years of Dividend Growth	n/a
Payout Ratio	59.51%
Buyback Yield	-1.58%
Shareholder Yield	0.19%
Earnings Yield	1.53%
FCF Yield	12.57%

Dividend Details

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Takeda Pharmaceutical has an Altman Z-Score of 1.11 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.11
Piotroski F-Score	6